XML 48 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenues:      
Revenues $ 102,428 $ 84,452 $ 36,567
Operating expenses:      
Research and development 145,922 114,866 65,728
General and administrative 61,686 46,736 27,200
Total operating expenses 207,608 161,602 92,928
Loss from operations (105,180) (77,150) (56,361)
Interest and other income, net 9,761 8,261 1,793
Loss before income taxes (95,419) (68,889) (54,568)
Benefit from income taxes 0 0 0
Net loss (95,419) (68,889) (54,568)
Net loss attributable to non-controlling interest (233) (555) 0
Net loss attributable to Sangamo Therapeutics, Inc. stockholders $ (95,186) $ (68,334) $ (54,568)
Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc. (in dollars per share) $ (0.85) $ (0.70) $ (0.70)
Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares) 112,114 96,941 78,084